Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

SELL
$48.48 - $57.85 $31,657 - $37,776
-653 Reduced 9.81%
6,005 $308,000
Q2 2023

Jul 25, 2023

SELL
$63.71 - $70.74 $5,096 - $5,659
-80 Reduced 1.19%
6,658 $425,000
Q1 2023

May 09, 2023

SELL
$65.71 - $74.53 $63,607 - $72,145
-968 Reduced 12.56%
6,738 $467,000
Q4 2022

Jan 26, 2023

SELL
$68.48 - $81.09 $53,072 - $62,844
-775 Reduced 9.14%
7,706 $0
Q3 2022

Nov 10, 2022

BUY
$0.13 - $76.84 $51 - $30,274
394 Added 4.87%
8,481 $603,000
Q2 2022

Jul 18, 2022

BUY
$72.62 - $79.98 $40,739 - $44,868
561 Added 7.45%
8,087 $623,000
Q1 2022

Apr 29, 2022

BUY
$61.48 - $73.72 $17,214 - $20,641
280 Added 3.86%
7,526 $550,000
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $40,222 - $46,890
750 Added 11.55%
7,246 $452,000
Q3 2021

Nov 04, 2021

SELL
$59.17 - $69.31 $123,191 - $144,303
-2,082 Reduced 24.27%
6,496 $384,000
Q2 2021

Aug 09, 2021

BUY
$61.91 - $67.42 $20,554 - $22,383
332 Added 4.03%
8,578 $573,000
Q1 2021

May 06, 2021

BUY
$59.34 - $66.74 $4,865 - $5,472
82 Added 1.0%
8,246 $521,000
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $38,512 - $43,641
667 Added 8.9%
8,164 $506,000
Q3 2020

Nov 10, 2020

BUY
$57.43 - $63.64 $1,722 - $1,909
30 Added 0.4%
7,497 $452,000
Q2 2020

Aug 11, 2020

BUY
$54.82 - $64.09 $148,452 - $173,555
2,708 Added 56.9%
7,467 $439,000
Q1 2020

May 05, 2020

SELL
$46.4 - $67.43 $14,384 - $20,903
-310 Reduced 6.12%
4,759 $265,000
Q4 2019

Jan 31, 2020

BUY
$49.21 - $64.19 $249,445 - $325,379
5,069 New
5,069 $325,000
Q4 2018

Jan 29, 2019

SELL
$48.76 - $63.23 $185,288 - $240,274
-3,800 Closed
0 $0
Q3 2018

Nov 05, 2018

SELL
$55.19 - $62.25 $39,626 - $44,695
-718 Reduced 15.89%
3,800 $236,000
Q1 2018

Apr 19, 2018

BUY
$59.92 - $68.98 $270,718 - $311,651
4,518 New
4,518 $286,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bigelow Investment Advisors, LLC Portfolio

Follow Bigelow Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bigelow Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bigelow Investment Advisors, LLC with notifications on news.